US 12,201,283 B2
Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
Theodore Charles Lamson, Pleasanton, CA (US); Joshua Makower, Los Altos Hills, CA (US); Joseph Catanese, III, Oakland, CA (US); Jacqueline Nerney Welch, Moraga, CA (US); Amrish Jayprakash Walke, Santa Clara, CA (US); Claude Vidal, Santa Barbara, CA (US); Russell J. Redmond, Goleta, CA (US); and Michael Collinson, Goleta, CA (US)
Assigned to Teleflex Life Sciences LLC, Wilmington, DE (US)
Filed by Teleflex Life Sciences LLC, Wilmington, DE (US)
Filed on Mar. 10, 2023, as Appl. No. 18/181,857.
Application 13/073,763 is a division of application No. 11/838,036, filed on Aug. 13, 2007, granted, now 7,914,542, issued on Mar. 29, 2011.
Application 11/838,036 is a division of application No. 11/134,870, filed on May 20, 2005, granted, now 7,758,594, issued on Jul. 20, 2010.
Application 18/181,857 is a continuation of application No. 16/798,112, filed on Feb. 21, 2020.
Application 16/798,112 is a continuation of application No. 16/107,447, filed on Aug. 21, 2018, granted, now 11,090,036, issued on Aug. 17, 2021.
Application 16/107,447 is a continuation of application No. 14/535,266, filed on Nov. 6, 2014, granted, now 10,105,132, issued on Oct. 23, 2018.
Application 14/535,266 is a continuation of application No. 13/844,020, filed on Mar. 15, 2013, granted, now 8,900,252, issued on Dec. 2, 2014.
Application 13/844,020 is a continuation of application No. 13/073,763, filed on Mar. 28, 2011, granted, now 8,734,468, issued on May 27, 2014.
Prior Publication US 2023/0293166 A1, Sep. 21, 2023
Int. Cl. A61B 17/04 (2006.01); A61B 17/00 (2006.01); A61B 17/02 (2006.01); A61B 17/06 (2006.01); A61B 17/34 (2006.01); A61B 17/42 (2006.01); A61B 18/00 (2006.01); A61F 2/04 (2013.01); A61F 2/82 (2013.01)
CPC A61B 17/00234 (2013.01) [A61B 17/0482 (2013.01); A61B 17/06109 (2013.01); A61B 2017/00022 (2013.01); A61B 2017/00274 (2013.01); A61B 2017/00792 (2013.01); A61B 2017/00796 (2013.01); A61B 2017/00805 (2013.01); A61B 17/0218 (2013.01); A61B 17/0401 (2013.01); A61B 2017/0404 (2013.01); A61B 2017/0409 (2013.01); A61B 2017/0417 (2013.01); A61B 2017/0419 (2013.01); A61B 2017/0451 (2013.01); A61B 2017/0454 (2013.01); A61B 2017/0456 (2013.01); A61B 2017/0458 (2013.01); A61B 2017/0462 (2013.01); A61B 2017/0464 (2013.01); A61B 17/0467 (2013.01); A61B 17/0469 (2013.01); A61B 17/0487 (2013.01); A61B 2017/0488 (2013.01); A61B 2017/06052 (2013.01); A61B 2017/06176 (2013.01); A61B 17/3468 (2013.01); A61B 17/3478 (2013.01); A61B 17/42 (2013.01); A61B 2018/00547 (2013.01); A61F 2002/041 (2013.01); A61F 2/82 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method for treating benign prostatic hyperplasia, comprising:
inserting an interventional device comprising a tubular elongate device coupled with a hollow needle defining a sharp distal tip longitudinally through a urethra of a subject until a distal portion of the tubular elongate device reaches a position within the urethra distal to a prostate gland;
positioning the distal portion of the tubular elongate device at a first target region and advancing the hollow needle from an opening in the distal portion of the tubular elongate device into a lateral lobe of the prostate gland at the first target region;
injecting a therapeutic agent from the distal portion of the needle into the lateral lobe at the first target region;
repositioning the distal portion of the tubular elongate device at a second target region and advancing the hollow needle from the opening in the distal portion of the tubular elongate device into the lateral lobe at the second target region;
injecting more of the therapeutic agent from the distal portion of the needle into the lateral lobe at the second target region, wherein the therapeutic agent causes the lateral lobe to decrease in size; and
viewing a position of the interventional device using an endoscopic device advanced to the prostatic urethra.